TRIAL OF OSTEOPOROSIS PREVENTION IN RACIALLY DIVERSE PROSTATE CANCER PATIENTS

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Osteoporosis and associated fractures are a major public health concern because of related morbidity, disability, decreased quality of life and mortality. Unfortunately, ignorance about prevention or treatment of osteoporosis in male patients on androgen deprivation for prostate cancer is widespread among health professionals, patients and the public at large. For example, the majority of American men view osteoporosis solely as a woman's disease" according to a Gallup survey published by the National Osteoporosis Foundation (1996). Health professionals too have not taken preventive measures due to lack of research and evidence in this area. In postmenopausal women, pharmacological options for treating and/or preventing osteoporosis include Calcium carbonate/ vitamin D combinations, estrogen replacement therapy, and oral bisphosphonate therapy among others. Similarly evidence suggests that in osteoporosis secondary to chronic glucocorticoid therapy and thyroid replacement therapy in male and female patients, treatment with intermittent intravenous bisphosphonate (pamidronate) therapy is effective.